Document is current
Any future updates will be listed below
-
Authors
Ring, Alistair
Sutherland, Stephanie
Harper-Wynne, Catherine
Owen, James
Sanglier, Thibaut
Velikova, Galina
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02393924 at ClinicalTrials.govDocuments that mention this clinical trial
A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable LA/MBC: final results of the ESTHER study
https://doi.org/10.1007/s10549-025-07708-4
- License Information
-
More Information
Article History
Received: 6 December 2024
Accepted: 22 April 2025
First Online: 13 May 2025
Declarations
:
: Alistair Ring has received consulting fees from Astrazeneca, Daiichi Sankyo, MSD; honoraria for talks from Novartis, Lilly, Pfizer, Zuellig Pharma. Stephanie Sutherland has received travel expenses from Roche. Catherine Harper-Wynne has no relevant financial or non-financial interests to disclose. James Owen is an employee of Roche Products Ltd. Thibaut Sanglier is an employee of F. Hoffmann-La Roche Ltd. Galina Velikova has received honoraria from Pfizer, Novartis, Eisai, Lilly; consulting fees from AstrzaZeneca, Roche, Novartis, Pfizer, Seagen, Eisai, Sanofi, Daiichi Sankyo; attended an unpaid AZ working group and received an institutional grant from Pfizer.
: This study approved by Nottingham Research Ethics Committee (14/EM/1307) and was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
: No individual person’s data are included this manuscript.
